Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX131 · 2 trials · 8 indications
For all cohorts: Incidence of Adverse events defined as dose-limiting toxicities
Phase 2 (expansion of selected Phase 1 disease types)
Phase 2 (expansion of selected Phase 1 disease types)
Defined as dose-limiting toxicities
ORR based on Independent Review Committee (IRC) assessment, defined as the proportion of subjects who have achieved a best overall response of CR or PR according to appropriate response evaluation criteria for each disease histology
| Arm | Type | Description |
|---|---|---|
| CTX131 | EXPERIMENTAL | Administered by IV infusion following lymphodepleting chemotherapy |
| Name | Type | Description |
|---|---|---|
| CTX131 | BIOLOGICAL | CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components |
Inclusion Criteria: 1. ≥18 years of age 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (ECOG status of 2 will be permitted for subjects with AML) 3. Diagnosed with r/r T Cell Lymphoma (TCL), B Cell Lymphoma (BCL), or Acute Myeloid Leukemia (AML) T cell lymphoma, including St...
CTX131 is an investigational therapy being studied for the treatment of relapsed or refractory solid tumors and hematologic malignancies. In clinical trials, it is evaluated in conditions including T Cell Lymphoma, Clear Cell Renal Cell Carcinoma, cervical carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, malignant pleural mesothelioma, B Cell Lymphoma, and Acute Myeloid Leukemia.
CTX131 is being developed by CRISPR Therapeutics AG, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CRSP.
CTX131 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in solid tumors and one in hematologic malignancies.
CTX131 has been evaluated in two completed Phase 1 trials. NCT05795595 studied CTX131 in adults with relapsed or refractory solid tumors, enrolling 19 participants in the United States. NCT06492304 studied CTX131 in adults with relapsed or refractory hematologic malignancies, enrolling 12 participants in the United States and Australia.
CTX131 is classified as a monoclonal antibody modality in its development program. However, the specific molecular target of CTX131 has not been disclosed in the available clinical trial information.